Drawing for INVETECH

USPTO serial 88472660

INVETECH

Reviewed by CopyMark Law Group

Reg. 6121954Status 702Renewal
Filing date
Status date
Registration date
Aug 11, 2020
Examiner
HILLIARD, JESSICA LYNN
Law office
Historical data usage

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with INVETECH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*

Plus Government fees of $1,275

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Thomas M. Palisi

Thomas M. Palisi Lerner David LLP20 Commerce DriveCranford, NJ 07016United States

Goods and services

ClassDescriptionStatusFirst use
037Installation, cleaning, repair and maintenance of scientific and medical devices for others; installation, cleaning, repair and maintenance of biomedical and scientific instrumentation, computer hardware and factory automation machinery in the fields of healthcare, biomedical, life sciences and cell and advanced therapies; providing advice, consultancy and information with regard to the aforesaid servicesACTIVE—
040Custom manufacture and assembly services, namely, custom manufacture and assembly of biomedical and scientific instrumentation; custom construction and manufacture of biomedical and scientific instrumentation; custom construction and manufacture of scientific and medical devices for others; custom construction and manufacture of biomedical and scientific instrumentation and computer hardware for use with biomedical and scientific instrumentation; custom construction and manufacturing in the fields of healthcare, biomedical, life sciences and cell and advanced therapies, namely, custom construction and manufacture of biomedical and scientific instrumentation for others; providing advice, consultancy and information with regard to the aforesaid servicesACTIVE—
042Science and technology services, namely, scientific research in the fields of diagnostics and life sciences, point of care diagnostics, and cell and advanced therapies; consultancy services, namely, technical consultancy in the fields of diagnostics and life sciences, point of care diagnostics, and cell and advanced therapies; engineering services; design and development services, namely, design and development of biomedical and scientific instrumentation; computer hardware development for biomedical and scientific instrumentation products; software design, development, programming and implementation in the fields of biomedical and scientific instrumentation; IT consulting services in the nature of IT consultancy, advisory and information services in the fields of biomedical and scientific instrumentation; Software as a Service (SAAS) services featuring software for database management in the fields of diagnostics and life sciences, point of care diagnostics, and cell and advanced therapies; scientific and technological consultancy services, namely, technological consulting services in the fields of diagnostics and life sciences technologies, point of care diagnostics technologies, and cell and advanced therapies technologies; consultancy services relating to design, development and engineering, namely, consulting services in the field of design and development of engineering processes in the fields of diagnostics and life sciences, point of care diagnostics, and cell and advanced therapies; consultancy services relating to the design, development, engineering, custom construction and manufacture of scientific and medical devices, and biomedical and scientific instrumentation, computer hardware and factory automation machinery for use in the fields of diagnostics and life sciences, point of care diagnostics, and cell and advanced therapies; Consulting services in the field of medical physics, namely, consultancy services in the fields of healthcare, biomedical, life sciences and cell and advanced therapies; scientific and technological engineering services in the fields of diagnostics and life sciences, point of care diagnostics, and cell and advanced therapies; engineering services in relation to scientific and medical devices, biomedical and scientific instrumentation and computer hardware and factory automation related to diagnostics and life sciences, point of care diagnostics, and cell and advanced therapies; engineering services in the fields of healthcare, biomedical, life sciences and cell and advanced therapies; scientific and technological design and development services, namely, design and development of computer software for operating biomedical and scientific instrumentation products; custom design and development services, namely, custom design and development of computer software for operating biomedical and scientific instrumentation products; process design and development services, namely, consulting services in the field of design and development of engineering processes for diagnostics and life sciences, point of care diagnostics, and cell and advanced therapies; product design and development in the fields of diagnostics and life sciences, point of care diagnostics, and cell and advanced therapies; product design and development of biomedical and scientific instrumentation; product design and development in the fields of healthcare, biomedical, life sciences and cell and advanced therapies; computer programming in the fields of healthcare, biomedical, life sciences and cell and advanced therapies; computer programming consultancy in the fields of healthcare, biomedical, life sciences and cell and advanced therapies; computer programming services relating to design, development and engineering in the fields of healthcare, biomedical, life sciences and cell and advanced therapies; computer programming services in the fields of healthcare, biomedical, life sciences and cell and advanced therapies; design, development, implementation, maintenance, updating and repair of computer software used in the fields of healthcare, biomedical, life sciences and cell and advanced therapies; design, development, installation, maintenance, updating and repair of computer software relating to the design, development, engineering, custom construction and manufacture of scientific and medical devices and related computer hardware and factory automation; design, development, installation, maintenance, updating and repair of computer software in the fields of healthcare, biomedical, life sciences, and cell and advanced therapies; computer software consultancy services in the fields of healthcare, biomedical, life sciences and cell and advanced therapies; providing advice, consultancy and information with regard to the aforesaid servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 17, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Oct 17, 2026C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Oct 17, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 7, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 7, 2026ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Oct 7, 2026EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Oct 7, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 7, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 29, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 29, 2026ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Sep 29, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 29, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 29, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 29, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 11, 2026E815TEAS SECTION 8 & 15 RECEIVED—
Aug 14, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 14, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 14, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 14, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Aug 14, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 11, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Nov 15, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 15, 2024ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Nov 15, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 15, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 11, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 26, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 26, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 26, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 26, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 26, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 6, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 22, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 16, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 16, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 15, 2020ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Apr 10, 2020GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Apr 10, 2020GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Apr 10, 2020CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 21, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 21, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 15, 2020ALIEASSIGNED TO LIE—
Mar 9, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 5, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 5, 2020ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Mar 5, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 5, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 11, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 11, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 11, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 4, 2019DOCKASSIGNED TO EXAMINER—
Jun 26, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 17, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance